skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

In June 2016, all United Nations Member States pledged to end the AIDS epidemic as a public health threat by 2030 and signed up to time-bound targets. These targets included reducing the number of people newly infected with HIV from 2.1 million in 2015, to fewer than 500,000 in 2020 and reducing the number of people dying from AIDS-related illnesses from 1.1 million in 2015, to fewer than 500,000 in 2020 [1]. These aggressive targets will only be possible with a holistic approach to both treatment and prevention of HIV infection. Effective antiretroviral drugs for the treatment of HIV had been approved for a number of years, however, despite initially promising vaccine candidates, a pharmacological approach to prophylaxis remained elusive. The approval of Truvada for HIV pre-exposure prophylaxis (PrEP) in 2012 changed this. The interactive infographic below charts the changing HIV prophylaxis trial landscape leading up to and following this key milestone.

 
[1] United Nations Sustainable Development Goals (June 2016) Bold new Political Declaration on Ending AIDS adopted in New York; Available from: https://www.un.org/sustainabledevelopment/blog/2016/06/bold-new-political-declaration-on-ending-aids-adopted-in-new-york/ [Accessed February 2019]




 

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。